Kadian may be considered as an individualized option for opioid use disorder when a clinician believes extended-release oral morphine could support more stable treatment. It is not automatically the best choice for everyone. The decision depends on current opioid use, medical history, previous treatment response, goals, medications, and safety factors.

This guide explains how Kadian fits within opioid agonist therapy (OAT), what an assessment may cover, how it compares with methadone, Suboxone, and Sublocade, and what to discuss before starting or changing treatment. It is educational information, not a diagnosis or prescribing recommendation.

Quick summary

• Kadian is a slow-release or extended-release oral morphine option used within clinician-supervised OAT.
• It may be discussed when methadone or buprenorphine-based treatment has not provided sufficient benefit, caused unacceptable side effects, or does not fit a person’s clinical needs.
• Road To Recovery describes its Kadian program as including evaluation, once-daily dosing, regular follow-ups, response monitoring, and treatment-plan adjustments.
• Tell the care team about every medication, substance, allergy, and health concern before treatment decisions are made.
• Road To Recovery offers outpatient opioid addiction treatment across Ontario, with new OAT intakes seen by a nurse followed by a physician on the same day they start.

What Is Kadian Treatment?

Kadian is an extended-release form of oral morphine. In opioid use disorder treatment, it is used as part of OAT, a medical approach intended to reduce cravings and prevent severe withdrawal under healthcare supervision. Health Canada’s overview of opioid use disorder treatment explains that OAT uses long-acting opioid medications that act more slowly and for longer in the body than short-acting opioids.

The purpose is not to produce a rapid high. Instead, a clinician-managed plan aims to provide more consistent symptom control so a person can focus on health, safety, daily responsibilities, and longer-term recovery goals. Individual responses vary, so the medication, dose, follow-up plan, and treatment duration must be determined by the clinical team.

Road To Recovery describes Kadian as an alternative for patients who need something different from methadone or Suboxone. Its program includes evaluation, regular follow-ups, response monitoring, and treatment-plan adjustments. Review the clinic’s Kadian program for details about evaluation, monitoring, interactions, and once-daily dosing.

For a broader explanation of how Kadian treatment uses slow-release oral morphine within OAT, readers can also review the clinic’s treatment guide. Kadian is one possible treatment pathway, not a medication to select without an assessment.

When Might a Clinician Consider Kadian?

A clinician may discuss Kadian when another OAT option has not provided enough benefit, caused unacceptable side effects, or does not align with the person’s clinical circumstances. Slow-release oral morphine may be considered when buprenorphine or methadone have not been sufficiently helpful or tolerated, but an individual assessment is still required.

Tell the clinician what you have tried, how consistently it was taken, whether withdrawal or cravings continued, which side effects occurred, and what made treatment difficult to continue. This helps distinguish a medication problem from an issue that might be addressed through dose adjustment, additional support, a different routine, or another approach.

Personal preference matters, but it does not replace safety screening. A clinician will consider your health, other medications and substances, current opioid use, practical needs, and treatment goals before recommending an option.

What to Expect During a Kadian Assessment

An assessment is a conversation about safety and fit, not a commitment to start Kadian. Be prepared to discuss current opioid use, recent treatment, withdrawal and craving patterns, other substance use, medical conditions, mental health concerns, allergies, and all prescribed, over-the-counter, and non-prescribed substances.

Explain what you want treatment to help you do. Goals may include reducing withdrawal, gaining daily stability, avoiding an unsafe opioid supply, returning to work, improving family life, or addressing mental health and addiction concerns together.

Road To Recovery states that its Kadian pathway includes an initial evaluation and regular follow-ups. The clinical team monitors response and can adjust the plan when symptoms, circumstances, or goals change. New opioid addiction treatment intakes are seen by a nurse followed by a physician on the same day they start, although same-day intake does not guarantee a particular medication or outcome.

Dosing, Monitoring, and Follow-Up

Road To Recovery describes Kadian as an extended-release option with once-daily dosing and consistent, all-day symptom control. The exact dose and instructions are individualized by the prescribing clinician. Do not alter the amount, timing, or method of taking it without clinical advice.

Follow-up allows the care team to ask about cravings, withdrawal, sedation, side effects, interactions, daily functioning, and changes in opioid or other substance use. It also provides an opportunity to discuss counselling, mental health support, referrals, and practical barriers to continuing care.

There is no universal answer to how long someone should remain on Kadian. Duration depends on response, safety, stability, goals, and ongoing clinical review. Ask how progress will be assessed and what would lead the team to continue, adjust, or reconsider the plan.

Kadian Compared With Methadone, Suboxone, and Sublocade

Each option has a different medication form and treatment routine. This comparison supports discussion with a clinician rather than ranking treatments.

Option	Medication form and pattern	Question to discuss
Kadian	Extended-release oral morphine, described by Road To Recovery as once daily	Could an extended-release oral option address my history, symptoms, and goals?
Methadone	Long-acting medication with daily dosing and a structured routine	Would methadone provide appropriate craving and withdrawal control?
Suboxone	Buprenorphine and naloxone taken as a daily film or tablet	Would buprenorphine offer the right balance of flexibility and symptom control?
Sublocade	Long-acting buprenorphine given as a monthly injection for clinically appropriate patients	Would fewer dosing decisions and a monthly appointment suit my needs?

A methadone maintenance program may offer another structured OAT pathway with supervised dosing, monitoring, and ongoing support. People comparing daily oral treatment with an injection can review Sublocade injection treatment to understand how monthly buprenorphine differs from Kadian’s oral dosing structure.

The practical choice is not simply about which medication sounds strongest or most convenient. Consider treatment history, safety, appointment routines, privacy needs, ability to attend follow-ups, and preference for daily or less frequent dosing.

Kadian Safety: Questions and Precautions to Discuss

Kadian is an opioid-based treatment, so safety depends on accurate information, prescribed use, and clinical monitoring. Road To Recovery advises patients to tell the care team about all medications and substances because interactions are possible.

• List every prescription medication, over-the-counter product, supplement, and substance you use.
• Tell the clinician about alcohol, sedatives, sleep medications, and other opioids, even if use is occasional.
• Ask which combinations may increase sedation or other risks.
• Follow prescribed directions and ask what to do if you miss a dose or feel unwell.
• Do not start, stop, increase, decrease, or combine treatment without clinical advice.
• Ask which symptoms require urgent medical attention and whom to contact outside regular appointments.

Do not assume a substance is safe to combine with Kadian because it is prescribed or available without a prescription. Complete information helps the team make a safer recommendation.

Questions to Bring to a Kadian Consultation

• Why are you considering Kadian instead of methadone, Suboxone, or Sublocade?
• What treatment history or safety factors influence that recommendation?
• How will you monitor cravings, withdrawal, side effects, and daily functioning?
• How often will follow-up appointments occur at the beginning?
• What should I do if symptoms change or I use another substance?
• What support is available for mental health concerns or other addictions?
• How will we review whether treatment is meeting my goals?

Bring a list of medications and allergies, details about recent opioid and other substance use, previous treatment names and dates if known, and concerns about transportation, work, family responsibilities, or confidentiality. You do not need every answer before requesting an assessment.

Starting Opioid Use Disorder Treatment in Ontario

Road To Recovery operates outpatient addiction treatment clinics across Ontario and describes its care as confidential, judgment-free, and personalized. Its network provides Kadian, methadone, Suboxone, and Sublocade, alongside mental health and addiction support.

The clinic reports that new opioid addiction treatment intakes are seen by a nurse followed by a physician on the same day they start. Intake can be initiated through a secure online portal. Same-day access can reduce delays, but it does not mean every person will receive Kadian or begin the same plan. The clinician must determine what is appropriate and safe.

Frequently Asked Questions

Is Kadian the same as methadone?

No. Kadian is an extended-release oral morphine option, while methadone is a different long-acting medication. Both may be used within OAT, but their clinical considerations and routines are not identical.

Who may be considered for Kadian treatment?

A person may be considered after an individualized assessment, particularly when methadone or buprenorphine-based treatment has not provided sufficient benefit or caused unacceptable side effects. Suitability cannot be determined from symptoms alone.

Can Kadian be considered after Suboxone or methadone?

It may be discussed when a clinician believes another option is needed because of response, side effects, or other clinical factors. Previous treatment details should be reviewed before changing medication.

How long might someone stay on Kadian?

There is no standard duration for everyone. The care team reviews response, safety, stability, and goals over time, then determines whether to continue or adjust treatment.

What medications and substances should I disclose?

Disclose prescriptions, over-the-counter medicines, supplements, alcohol, sedatives, other opioids, and recreational substances. Interactions are possible, and complete information supports safer planning.

Can I ask about Kadian during a same-day intake in Ontario?

Yes. Raise Kadian during the assessment and bring your treatment history, current medications, substance-use information, and goals. The clinician decides which treatment is appropriate.

Choosing the Next Step With Kadian Treatment

Kadian is one clinician-guided option for opioid use disorder treatment. Its extended-release, once-daily structure may be worth discussing when other OAT options have not been suitable, but the right decision depends on medical history, treatment response, current opioid use, other substances, safety concerns, and practical needs.

Prepare by listing medications, allergies, treatment history, current use, and goals. Ask how Kadian compares with methadone, Suboxone, and Sublocade, how monitoring will work, and what support is available if circumstances change.

To begin an outpatient assessment and discuss opioid agonist therapy options in Ontario, contact Road To Recovery.